France Blood Glucose Monitoring Market Size (2024 - 2029)

The France Blood Glucose Monitoring Market is projected to experience growth over the forecast period, driven by an increasing prevalence of diabetes and obesity, alongside heightened awareness and advancements in diabetic care technology. The market's expansion is supported by France's centralized healthcare system, which facilitates national-level reimbursement decisions, impacting the accessibility and adoption of diabetes care devices. These factors collectively contribute to the anticipated growth in the market size during the analysis period.

Market Size of France Blood Glucose Monitoring Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
France Blood Glucose Monitoring Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 0.87 Billion
Market Size (2029) USD 1.31 Billion
CAGR (2024 - 2029) 8.50 %

Major Players

France Blood Glucose Monitoring Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

France Blood Glucose Monitoring Market Analysis

The France Blood Glucose Monitoring Market size is estimated at USD 0.87 billion in 2024, and is expected to reach USD 1.31 billion by 2029, growing at a CAGR of 8.5% during the forecast period (2024-2029).

One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the coronavirus disease-2019 (COVID-19) pandemic epidemic. Diabetes has previously been identified as a significant risk factor for death in individuals infected with either the Middle East respiratory syndrome-related coronavirus (MERS-CoV) or the 2009 H1N1 pandemic influenza. More recently, one of the main comorbidities linked to COVID-19 has consistently been diabetes.

Diabetes has the highest prevalence among all chronic conditions covered 100% by France's statutory health insurance (SHI), and the number of covered patients has doubled in the past 10 years. France is one of the major countries in the Europe region. According to the World Health Organization (WHO), about a million are diagnosed with diabetes in France. The prevalence of diabetes is growing among all ages in France, which can be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles of people. Furthermore, approximately 0.26 million are estimated to live with Type 1 diabetes in the region. Thus, the rising prevalence of diabetes and obesity, growing awareness, regarding diabetic care, healthcare expenditure, and technological advancements are a few factors that are further driving the market for diabetes care devices in France. In France, there is a centralized health care system their all the reimbursement decisions are taken at a national level and then applies to all of the countries. For diabetes technological devices in France, the reimbursement is based on the tariff system.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

France Blood Glucose Monitoring Industry Segmentation

Blood Glucose Monitoring Devices are used to diagnose both hyperglycemic and hypoglycemic conditions in diabetic patients. France Blood Glucose Monitoring Market is segmented into Type (Self-monitoring Blood Glucose and Continuous Glucose Monitoring), Component (Glucometer Devices, Test Strips, Lancets, Sensors, and Durables). The report offers the value (in USD million) and volume (in Units million) for the above segments.

Self-monitoring Blood Glucose Devices
Glucometer Devices
Test Strips
Lancets
Continuous Blood Glucose Monitoring Devices
Sensors
Durables (Receivers and Transmitters)
Need A Different Region Or Segment?
Customize Now

France Blood Glucose Monitoring Market Size Summary

The France blood glucose monitoring market is poised for significant growth, driven by the increasing prevalence of diabetes and obesity, alongside advancements in healthcare technology. Diabetes, a major chronic condition, is fully covered by France's statutory health insurance, with a notable rise in the number of patients over the past decade. The growing obese population, unhealthy diets, and sedentary lifestyles contribute to the rising diabetes cases across all age groups in France. This trend is further exacerbated by the COVID-19 pandemic, where diabetes has been identified as a significant risk factor for severe outcomes. The French healthcare system's centralized approach to reimbursement, based on a tariff system, supports the adoption of diabetes care devices, including continuous glucose monitors (CGMs) and self-monitoring blood glucose (SMBG) devices. These devices are becoming increasingly cost-effective and technologically advanced, offering real-time glucose monitoring and trend analysis, which are crucial for effective diabetes management.

The market landscape is characterized by a mix of major and generic players, with companies like Dexcom, Medtronic, Abbott, and Senseonics leading the CGM segment, while Roche, LifeScan, Arkray, and Ascensia dominate the BGM market. Recent technological innovations have bolstered the market presence of these companies, with notable developments such as Dexcom's G7 CGM system and Roche's new point-of-care blood glucose monitor. The rise in national awareness and the push for immediate access to medical innovations are expected to further drive the adoption of blood glucose monitoring devices in France. As these devices become more affordable and integrated with new technologies, the market is anticipated to experience steady growth, addressing the needs of the growing diabetic population and ensuring their well-being.

Explore More

France Blood Glucose Monitoring Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Drivers

    3. 1.3 Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Self-monitoring Blood Glucose Devices

      1. 2.1.1 Glucometer Devices

      2. 2.1.2 Test Strips

      3. 2.1.3 Lancets

    2. 2.2 Continuous Blood Glucose Monitoring Devices

      1. 2.2.1 Sensors

      2. 2.2.2 Durables (Receivers and Transmitters)

France Blood Glucose Monitoring Market Size FAQs

The France Blood Glucose Monitoring Market size is expected to reach USD 0.87 billion in 2024 and grow at a CAGR of 8.5% to reach USD 1.31 billion by 2029.

In 2024, the France Blood Glucose Monitoring Market size is expected to reach USD 0.87 billion.

France Blood Glucose Monitoring Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)